Meet our Management Team

As CEO, Mr. Gregg is responsible for managing operations for AmbioPharm and serves on the Board of Directors. Prior to AmbioPharm, he had long and successful career at Bachem, a company specializing in the development and manufacture of peptides and oligonucleotides, where he held for 8 years the position of COO for Bachem Americas. In his extensive career at Bachem, Mr. Gregg has held a variety of positions in peptide manufacturing, quality and compliance, and operations management. His skills include driving business and operational growth and strategic acquisition and integration. He holds an MBA from San Diego State University and a BA in Chemistry from the University of California, San Diego.

Mr. Kiel is the Chief Financial Officer of Ambio Pharmaceuticals, the parent company of AmbioPharm. He is also Secretary/Treasurer of the Company and member of the Board since its formation in 2014. He is also primarily responsible for all capital markets activity.
As CFO, Mr. Kiel is responsible for the financial health of the organization, including accounting, financial reporting, cash management, and relations with investors, banks and government. He actively participates in negotiations and contract review,
He was previously a Partner at Deloitte Consulting, one of the nation’s Big Four accounting firms. He holds an MBA from The Ohio State University and was awarded a CPA (now inactive) and Series 7 license.